Who owns Monte Rosa Therapeutics, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of GLUE from SEC Form 13F filings across 190 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 190 institutions disclosed 92.4M shares of Monte Rosa Therapeutics, Inc. worth $1.10B — about 90.8% of shares outstanding; the largest disclosed holder is PRICE T ROWE ASSOCIATES INC /MD/. Source: SEC Form 13F filings, parsed by EvidInvest.
190
13F holders
$1.10B
value, 2026 filers
90.8%
of shares outstanding (92.4M sh)
39
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of GLUE's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | PRICE T ROWE ASSOCIATES INC /MD/ | 7.4M | $87.8M | 0.0% | 7.2% | -17.0% |
| 2 | BlackRock, Inc. | 7.2M | $85.8M | 0.0% | 7.1% | +5.1% |
| 3 | Vestal Point Capital, LP | 7.1M | $85.1M | 2.2% | 7% | +55.0% |
| 4 | NEA Management Company, LLC | 6.7M | $79.8M | 5.9% | 6.6% | -13.0% |
| 5 | BAKER BROS. ADVISORS LP | 4.3M | $51.8M | 0.2% | 4.3% | 0.0% |
| 6 | BVF INC/IL | 4.3M | $51.0M | 1.7% | 4.2% | -4.1% |
| 7 | TCG Crossover Management, LLC | 3.8M | $45.1M | 1.3% | 3.7% | -18.2% |
| 8 | STATE STREET CORP | 3.7M | $44.4M | 0.0% | 3.7% | -0.2% |
| 9 | VANGUARD CAPITAL MANAGEMENT LLC | 3.5M | $41.5M | 0.0% | 3.4% | +1.8% |
| 10 | Versant Venture Management, LLC | 3.2M | $37.9M | 34.8% | 3.1% | 0.0% |
| 11 | SILVERARC CAPITAL MANAGEMENT, LLC | 3.1M | $37.1M | 4.3% | 3.1% | +180.9% |
| 12 | MONTANOVA CAPITAL, LLC | 2.9M | $34.8M | 0.8% | 2.9% | -17.9% |
| 13 | BRAIDWELL LP | 2.5M | $30.1M | 1.3% | 2.5% | +3.0% |
| 14 | GEODE CAPITAL MANAGEMENT, LLC | 1.9M | $22.2M | 0.0% | 1.8% | -0.3% |
| 15 | Aisling Capital Management LP | 1.6M | $18.6M | 6.2% | 1.5% | 0.0% |
| 16 | DIMENSIONAL FUND ADVISORS LP | 1.4M | $16.5M | 0.0% | 1.4% | +17.3% |
| 17 | MORGAN STANLEY | 1.1M | $13.7M | 0.0% | 1.1% | +45.3% |
| 18 | MPM BIOIMPACT LLC | 1.1M | $13.4M | 1.0% | 1.1% | -3.1% |
| 19 | Opaleye Management Inc. | 1.0M | $12.3M | 1.4% | 1% | +38.9% |
| 20 | ADAR1 Capital Management, LLC | 1.0M | $12.0M | 0.5% | 1% | +364.9% |
| 21 | Frazier Life Sciences Management, L.P. | 1.0M | $11.9M | 0.3% | 1% | 0.0% |
| 22 | GOLDMAN SACHS GROUP INC | 871,795 | $10.4M | 0.0% | 0.9% | -12.7% |
| 23 | CITADEL ADVISORS LLC | 857,107 | $10.2M | 0.0% | 0.8% | +424.0% |
| 24 | Point72 Asset Management, L.P.NEW | 770,673 | $9.2M | 0.0% | 0.8% | new |
| 25 | Nextech Invest Ltd. | 761,153 | $9.1M | 0.4% | 0.7% | 0.0% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.